BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for its oral Factor D inhibitor, BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria.

CaPre achieved a 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint

Previously completed positive, pivotal ADVANCE-1 trial sufficient with single additional Phase 3 efficacy trial for NDA in Alzheimer’s disease agitation Initiation of Phase 3, placebo-controlled, randomized-withdrawal efficacy trial on track for 4Q 2020 Initiation of long-term safety trial in patients with Alzheimer’s disease agitation expected in 4Q 2020 No treatments are currently approved for the treatment of Alzheimer’s disease agitation

Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced its Guangzhou

~Program to Focus on Advances and Breakthroughs in MS Research, Diagnostics and Technology~ ~Special Press Events Planned to Give Media Access to Key Leaders & Late Breaker Investigators~ MIDDLETON, Wis. , Aug. 31, 2020 /PRNewswire/ -- The 8 th Joint ACTRIMS-ECTRIMS Meeting, the largest international conference focused on Multiple Sclerosis (MS) research, w

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, SIGA’s Chief Scientific Officer, has been named a recipient of the 2021 American Society for Microbiology (ASM) Award for Applied and Biotechnological Research . The award recognizes an outstanding scientist with distinguished research achievements in the development of products, pro

Reports rapid advancement of COVID-19 antibody programs; combination studies achieve nearly complete neutralization of SARS-CoV-2

The world market for in vitro diagnostics (IVD) will reach $83.3 billion in revenues in 2020, according to a recently published report from Kalorama Information, The Worldwide Market for In Vitro Diagnostics . This includes instruments, reagents, kits and equipment-related software and services. Kalorama has just released the 1

Transparency Market Research has published a new report titled ‘Aesthetic Laser and Energy Devices Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2028.’ According to the new report, the global aesthetic laser and energy devices market was valued at US$ 1,953.0 Mn in 2017 and is projected to expand at a CAGR of 9.7% from 2018 to 2026.

Hansa Biopharma has been invited to participate in several leading global healthcare conferences during the Fall 2020.